We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
21 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Cannabidiol
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Beclometasone dipropionate/ formoterol fumarate/ glycopyrronium bromide
-
Prescription medicine decision summaryTGA decision: Epidyolex (cannabidiol) is approved as adjunctive therapy for seizures associated with Dravet and Lennox-Gastaut syndrome
-
Prescription medicine registrationActive ingredients: cannabidiol.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Dinutuximab beta
-
Prescription medicine registrationActive ingredients: beclometasone dipropionate; formoterol (eformoterol) fumarate dihydrate; glycopyrronium bromide (glycopyrrolate).
-
-
Prescription medicine registrationActive ingredients: dinutuximab beta.
-
Prescription medicine registrationActive ingredients: beclometasone dipropionate; formoterol (eformoterol) fumarate dihydrate.
-